SEC Form 4 · accession 0001209191-17-008830
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Haqq
Officer — EVP, R&D & Chief Scientific Of
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 5:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 6, 2017 | A | 49,500 | $0.00 | A | 413,605 | D | |
| Common StockF2 | holding | — | — | — | 17,312 | I | See footnote | |
| Common StockF3 | holding | — | — | — | 2,688 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service.
- F2The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- F3The shares are held by The Havenside Trust, of which the Reporting Person is trustee.